HLA-B27, Blood
Use
This test is used to assist in the diagnostic process of ankylosing spondylitis, juvenile rheumatoid arthritis, and reactive arthritis. The presence of the human leukocyte antigen (HLA)-B27 is associated with these conditions, though the exact mechanism of the association is not understood and is thought to be due to linkage disequilibrium. HLA-B27 is present in a significant portion of patients with these diseases.
Special Instructions
Not provided.
Limitations
HLA-B27 testing is not diagnostic on its own and should be interpreted in the context of clinical findings and other diagnostic procedures. The test may give false negatives or positives in individuals of certain ethnic backgrounds, especially if the HLA-B*27:06 allele is present, which is more common in those of Asian ethnicity and not associated with ankylosing spondylitis.
FDA ApprovedNew York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
HLA-B27
Other
LOINC Codes
- 26028-1 - HLA-B27 Ql FC
- 26028-1 - HLA-B27 Ql FC
- 96625-9 - HLA typ comm-Imp
Result Turnaround Time
2-14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
6 mL
Minimum Volume
1 mL
Container
Lavender top (EDTA)
Collection Instructions
Send whole blood specimen in original tube. Do not aliquot.
Storage Instructions
Specimen must arrive within 96 hours of collection.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 days |